When Hard Data Are Sparse, FDA Looks To The Experts
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Given the small dataset supporting the Arzerra BLA, FDA made up for the lack of solid data with exhaustive analysis and plentiful expert consultation